Wepon's sales subsidiary fined for abuse of dominance in China's bromhexine hydrochloride market
MLex Summary: Wepon Group Zhejiang Pharmaceutical Sales has been fined 2,241,754 yuan ($341,960), equivalent to 3 percent of its revenue for 2019, by the Zhejiang provincial Administration for Market Regulation for...To view the full article, register now.
Already a subscriber? Click here to view full article